{
    "nctId": "NCT03577743",
    "briefTitle": "Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer",
    "officialTitle": "Phase 2 Study to Evaluate the Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Triple Negative Breast Cancer, Safety Issues, Efficacy",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 54,
    "primaryOutcomeMeasure": "- progression free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patient firstly diagnosed with metastatic TNBC or after adjuvant treatment OF TNBC by immune histochemistry and biopsy\n2. Age \\>18 Y\n3. Performance status (PS ) 0-2\n4. Did not have any bleeding disorders.\n5. Receive only one line of chemotherapy in adjuvant ttt\n\nExclusion Criteria:\n\n1. Male patient\n2. PS \\>2\n3. Uncontrolled HPTN\n4. Have history of bleeding disorders\n5. Receive \\> one line of chemotherapy\n6. Have other type of malignancy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}